📢Travel Grant Opportunity for #ECRs

🙌Proud to announce that #EFIS, together with the @eurjimmunol.bsky.social, is offering 5 travel grants (€1,000 each) to support attendance at the GRC!

💡Grants will be awarded based on scientific merit, career stage + inclusion criteria.

⏰Deadline: 1 May 2026

With @hiroshi-ichise.bsky.social, closing the @ccii-kyoto.bsky.social workshop on advanced imaging and image analysis in Kyoto.

Thanks to Guolan Lu (Stanford), @iannaconelab.bsky.social, Andrea Radtke (Leica), Yuki Sugiura (CCII), and Johanne T. Jacobsen for great lectures and practicals!

Matteo Iannacone @iannaconelab.bsky.social gave a tour de force presentation on liver immunity, hosted by @hiroshi-ichise.bsky.social as part of the CCII workshop on Advanced Tissue Imaging & Image Analysis
#Immunology #TissueImmunity
www.ccii.med.kyoto-u.ac.jp/en/event/eve...

Review @natrevimmunol.nature.com @gustaveroussy.fr @iannaconelab.bsky.social
Kupffer cells in liver homeostasis and disease: from immune sentinels to metabolic gatekeepers
www.nature.com/articles/s41...

Great fun to write this review on Kupffer cells with Florent Ginhoux and Paul Kubes, covering origin, diversity and roles in immunity and metabolism, now out in @natrevimmunol.nature.com. Huge credit to Bruna Araujo David, Francesco Andreata and Camille Blériot for driving this work. t.co/rGpmTMRddV

This calls for a shift in vaccine design:

• target early, conserved viral proteins

• build tissue-resident immunity

• combine antibodies and T cells

Great collaboration with

Leo Swadling, Valeria Fumagalli and Mala K. Maini

Implications:

• T cells can act at inception, not just during clearance

• Standard readouts (serology/PCR) miss these events

• True exposure and immunity are likely underestimated

→ We need to measure what T cells actually do

What is abortive infection?

Virus enters cells → limited early replication →
🛑 Pre-existing memory T cells eliminate infected cells

Before there is:
• detectable viral load (PCR)
• antibody induction (seroconversion)
• clinical disease

→ infection is stopped “below the radar”

Abortive infection: T cells as early, antibody-independent defenders Nature Reviews Immunology - Neutralizing antibodies are widely viewed as the frontline of antiviral defence. Yet emerging evidence reveals that T cells can terminate infection before it is...

Neutralizing antibodies are not the whole story.

In our Comment in Nature Reviews Immunology, we highlight an alternative mode of protection:
👉 T cells can eliminate infection at its earliest stage — before it becomes detectable

We term this “abortive infection”

🔗 rdcu.be/fbq8p

Thread 1/4

Tissue and Spatial Immunology | Keystone Symposia Join us at the Keystone Symposia on Tissue and Spatial Immunology, February 2027, in Banff, with field leaders!

Excited to organize @keystoneSymposia.bsky.social Tissue and Spatial Immunology with @leilaakkari.bsky.social and Hai Qi in February 2027! Join us to explore emerging research in Banff! keysym.us/KSSpatialImmune27 #KSSpatialImmune27

Join us for the 2026 GRC Immunochemistry and Immunobiology "Immune Circuitry and Molecular Pathways in Tissue Homeostasis, Infection, and Disease" in beautiful Barcelona. June 28 - July 3, 2026. Great lineup of speakers! www.grc.org/immunochemis...

Don't miss the 2026 Global Immunotalks!

📢Want to speak at the #CancerImmuno conference?
Good news! The chairs have released additional short talk slots and extended the submission deadline to 26 February 2026!
Submit your abstract for a chance to present your work alongside leading researchers in the field.
👉 Register now: bit.ly/3NRB7Iu

📩 Submit the paper link + short statement (≤250 words) to ejied@wiley.com by 15 April 2026.
The winner will be selected by EJI editors together with @yefis-immunology.bsky.social representatives.

#Immunology #ImmunoSky #AcademicSky #EarlyCareerResearchers #ECR

@efis-immunology.bsky.social

European Journal of Immunology: EJI-EFIS Prize for the ECR Article of the Year EJI and EFIS are thrilled to announce a new prize honoring Early Career Researchers (ECRs) whose work is published in EJI. This initiative aims to showcase the next generation of immunologists and encourage them to submit their excellent research to EJI.

🏆Nominations are OPEN for the 2026 EJI-EFIS Prize for the ECR Article of the Year!

Best paper published in EJI (2025) by an early-career researcher wins €5,000 + travel grant to ECI 2027 (Florence)✈️

🔗 Details & eligibility: bit.ly/41GeiMi
🫵 Self-nominations encouraged!

Platelet-derived integrin- and tetraspanin-enriched tethers exacerbate severe inflammation Platelet integrin αIIbβ3 is essential for hemostasis, thrombosis, and inflammation. We found that ligation of αIIbβ3 by von Willebrand factor or fibrin under flow triggered its accumulation in plasma ...

Great story from the Nieswandt lab in Science: uncovering a non-classical platelet mechanism that drives inflammation via integrin- and tetraspanin-rich tethers. A fresh angle on thrombo-inflammation. Happy to be part of this work!
www.science.org/doi/10.1126/...

Thanks to Chiara Perucchini and Chiara Vespari for their critical contribution

Optimising Recovery of Hepatic Regulatory T Cells: A Practical Guide Using ARTC2 Blockade This is an update to the Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition), Chapter 3: 12C, by Cossarizza et al. Administration of anti-ARTC2 nanobody...

9/ Read the paper here 👉 onlinelibrary.wiley.com/doi/10.1002/...

And stay tuned — exciting new discoveries on liver Tregs are coming soon 👀🧬

Optimising Recovery of Hepatic Regulatory T Cells: A Practical Guide Using ARTC2 Blockade This is an update to the Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition), Chapter 3: 12C, by Cossarizza et al. Administration of anti-ARTC2 nanobody...

7/ Bottom line: this work reframes ARTC2 blockade from a default reagent to a rational, cost-effective experimental choice.

8/ Proud of the team — led by Caitlin Abbott, with Violette Mouro and colleagues — for turning a technical challenge into actionable guidance for the field.

Optimising Recovery of Hepatic Regulatory T Cells: A Practical Guide Using ARTC2 Blockade This is an update to the Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition), Chapter 3: 12C, by Cossarizza et al. Administration of anti-ARTC2 nanobody...

6/ Practical takeaway 💡

• Studying activated/eTregs at steady state? ARTC2 blockade may be optional.

• Profiling CD44^mid Tregs or working in inflammatory settings? ARTC2 blockade is essential.

Optimising Recovery of Hepatic Regulatory T Cells: A Practical Guide Using ARTC2 Blockade This is an update to the Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition), Chapter 3: 12C, by Cossarizza et al. Administration of anti-ARTC2 nanobody...

5/ Key insight: hepatic Treg subsets are not equally sensitive to ARTC2–P2RX7 activation.

Less-activated, tissue-resident Tregs are preferentially lost or skewed without protection.

Optimising Recovery of Hepatic Regulatory T Cells: A Practical Guide Using ARTC2 Blockade This is an update to the Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition), Chapter 3: 12C, by Cossarizza et al. Administration of anti-ARTC2 nanobody...

4/ During liver inflammation, ARTC2 blockade becomes critical: it boosts overall Treg yield and prevents phenotypic distortion — again with the strongest effect on CD44^mid Tregs.

Optimising Recovery of Hepatic Regulatory T Cells: A Practical Guide Using ARTC2 Blockade This is an update to the Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition), Chapter 3: 12C, by Cossarizza et al. Administration of anti-ARTC2 nanobody...

3/ At steady state, ARTC2 blockade has a selective benefit: it markedly improves recovery and preserves phenotype of CD44^mid (less-activated) Tregs, while having minimal impact on effector-like eTregs.

Optimising Recovery of Hepatic Regulatory T Cells: A Practical Guide Using ARTC2 Blockade This is an update to the Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition), Chapter 3: 12C, by Cossarizza et al. Administration of anti-ARTC2 nanobody...

1/ New from our lab 🧪
ARTC2 blockade is widely used to protect tissue Tregs — but when is it truly essential, and for which subsets?

2/ In this @eurjimmunol.bsky.social update, we dissect the subset-specific and context-dependent effects of ARTC2 blockade on hepatic Treg recovery.

Guidelines for T cell nomenclature - Nature Reviews Immunology This Consensus Statement clarifies the existing subset-based nomenclature for T cells. Furthermore, it proposes an alternative modular nomenclature that is designed to be brief and flexible and to avo...

Thrilled to contribute to this landmark consensus effort led by Dave Masopust and Rafi Ahmed. A major step toward clearer, shared T cell nomenclature for the field. www.nature.com/articles/s41...

CD4+ T cells license Kupffer cells to reverse CD8+ T cell dysfunction induced by hepatocellular priming - Nature Immunology Here the authors show that CD4+ effector T cells prevent or reverse CD8+ T cell dysfunction by licensing Kupffer cells to trigger IL-27 production, defining a liver-specific immune circuit and a poten...

Honoured to see our @natimmunol.nature.com study highlighted in a thoughtful @jhepatology.bsky.social commentary on the IL-27/Kupffer cell axis in chronic HBV — a great summary of why tissue immunity matters and of our work.

Paper: tinyurl.com/yt652mxa
Commentary: tinyurl.com/56pke5x5

New review out! 😊 20 years after it’s discovery, with @iannaconelab.bsky.social we decided to bring together what we currently know about this cytokine and how it shapes CD8 T cell responses. A small contribution to make sense of a field that is moving fast 🌈 @cp-trendsimmuno.bsky.social

Reframing IL-27: a central regulator of CD8+ T cell immunity Interleukin-27 (IL-27), a member of the IL-12 cytokine family, was long viewed primarily as a regulator of CD4+ T cell immunity. Subsequent studies re…

New review out in @cp-trendsimmuno.bsky.social! With @valentinavenzin.bsky.social, we revisit IL-27 as a central regulator of CD8⁺ T cell fate — integrating insights from infection, cancer, and autoimmunity, and outlining its therapeutic potential. www.sciencedirect.com/science/arti...

#CancerImmuno speaker list is live!📢
Join us in sunny Lisbon, July 2026. Register now and submit your talk to share your research.
Early Bird Deadline: 15 Jan 2026
👉 Click here to register: bit.ly/4qZVqmd
#FusionImmunology #FusionCancerResearch

🎤 Our next episode it out!

We chat with Professor Matteo Iannacone ( @iannaconelab.bsky.social ) from @@unisr.bsky.socialabout his work understanding the generation of dysfunctional adaptive immune cells in chronic #HepatitisBVirus infection.

🎧 Listen now: https://bit.ly/4o2W8xa